139 related articles for article (PubMed ID: 35919880)
1. Absolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus.
Hilvo M; Jylhä A; Lääperi M; Jousilahti P; Laaksonen R
Eur Heart J Open; 2021 Nov; 1(3):oeab010. PubMed ID: 35919880
[TBL] [Abstract][Full Text] [Related]
2. Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.
Havulinna AS; Sysi-Aho M; Hilvo M; Kauhanen D; Hurme R; Ekroos K; Salomaa V; Laaksonen R
Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2424-2430. PubMed ID: 27765765
[TBL] [Abstract][Full Text] [Related]
3. CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: A systematic review and meta-analysis.
Papazoglou AS; Stalikas N; Moysidis DV; Otountzidis N; Kartas A; Karagiannidis E; Giannakoulas G; Sianos G
J Clin Lipidol; 2022; 16(3):272-276. PubMed ID: 35219648
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy.
Hilvo M; Wallentin L; Ghukasyan Lakic T; Held C; Kauhanen D; Jylhä A; Lindbäck J; Siegbahn A; Granger CB; Koenig W; Stewart RAH; White H; Laaksonen R;
J Am Heart Assoc; 2020 May; 9(10):e015258. PubMed ID: 32375553
[TBL] [Abstract][Full Text] [Related]
5. Comparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients.
Leiherer A; Mündlein A; Laaksonen R; Lääperi M; Jylhä A; Fraunberger P; Drexel H
Eur J Prev Cardiol; 2022 May; 29(6):947-956. PubMed ID: 34417607
[TBL] [Abstract][Full Text] [Related]
6. Plasma Ceramides and Cardiovascular Events in Hypertensive Patients at High Cardiovascular Risk.
Yin W; Li F; Tan X; Wang H; Jiang W; Wang X; Li S; Zhang Y; Han Q; Wang Y; Du J
Am J Hypertens; 2021 Nov; 34(11):1209-1216. PubMed ID: 34232291
[TBL] [Abstract][Full Text] [Related]
7. Ceramide stearic to palmitic acid ratio predicts incident diabetes.
Hilvo M; Salonurmi T; Havulinna AS; Kauhanen D; Pedersen ER; Tell GS; Meyer K; Teeriniemi AM; Laatikainen T; Jousilahti P; Savolainen MJ; Nygård O; Salomaa V; Laaksonen R
Diabetologia; 2018 Jun; 61(6):1424-1434. PubMed ID: 29546476
[TBL] [Abstract][Full Text] [Related]
8. The Novel Ceramide- and Phosphatidylcholine-Based Risk Score for the Prediction of New-Onset of Hypertension.
Shoghli M; Lokki AI; Lääperi M; Sinisalo J; Lokki ML; Hilvo M; Jylhä A; Tuomilehto J; Laaksonen R
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137595
[TBL] [Abstract][Full Text] [Related]
9. Ceramides and Phosphatidylcholines Associate with Cardiovascular Diseases in the Elderly.
Katajamäki TT; Koivula MK; Hilvo M; Lääperi MTA; Salminen MJ; Viljanen AM; Heikkilä ETM; Löppönen MK; Isoaho RE; Kivelä SL; Jylhä A; Viikari L; Irjala KM; Pulkki KJ; Laaksonen RMH
Clin Chem; 2022 Dec; 68(12):1502-1508. PubMed ID: 36308332
[TBL] [Abstract][Full Text] [Related]
10. Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.
Gencer B; Morrow DA; Braunwald E; Goodrich EL; Hilvo M; Kauhanen D; Sabatine MS; Laaksonen R; O'Donoghue ML
Eur J Prev Cardiol; 2022 May; 29(6):895-902. PubMed ID: 33624052
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.
Hilvo M; Meikle PJ; Pedersen ER; Tell GS; Dhar I; Brenner H; Schöttker B; Lääperi M; Kauhanen D; Koistinen KM; Jylhä A; Huynh K; Mellett NA; Tonkin AM; Sullivan DR; Simes J; Nestel P; Koenig W; Rothenbacher D; Nygård O; Laaksonen R
Eur Heart J; 2020 Jan; 41(3):371-380. PubMed ID: 31209498
[TBL] [Abstract][Full Text] [Related]
12. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
Laaksonen R; Ekroos K; Sysi-Aho M; Hilvo M; Vihervaara T; Kauhanen D; Suoniemi M; Hurme R; März W; Scharnagl H; Stojakovic T; Vlachopoulou E; Lokki ML; Nieminen MS; Klingenberg R; Matter CM; Hornemann T; Jüni P; Rodondi N; Räber L; Windecker S; Gencer B; Pedersen ER; Tell GS; Nygård O; Mach F; Sinisalo J; Lüscher TF
Eur Heart J; 2016 Jul; 37(25):1967-76. PubMed ID: 27125947
[TBL] [Abstract][Full Text] [Related]
13. Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes.
Wretlind A; Curovic VR; Suvitaival T; Theilade S; Tofte N; Winther SA; Vilsbøll T; Vestergaard H; Rossing P; Legido-Quigley C
Diabetes; 2023 Oct; 72(10):1493-1501. PubMed ID: 37478203
[TBL] [Abstract][Full Text] [Related]
14. Ceramides and phospholipids in plasma extracellular vesicles are associated with high risk of major cardiovascular events after carotid endarterectomy.
Timmerman N; Waissi F; Dekker M; de Borst GJ; van Bennekom J; de Winter RJ; Hilvo M; Jylhä A; Pasterkamp G; de Kleijn DPV; Laaksonen R
Sci Rep; 2022 Apr; 12(1):5521. PubMed ID: 35365690
[TBL] [Abstract][Full Text] [Related]
15. Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes.
Mantovani A; Altomari A; Lunardi G; Bonapace S; Lippi G; Bonnet F; Targher G
Diabetes Metab; 2020 Sep; 46(4):326-330. PubMed ID: 31185304
[TBL] [Abstract][Full Text] [Related]
16. Ceramides: a potential cardiovascular biomarker in young adult childhood cancer survivors?
Broberg O; Weismann CG; Øra I; Wiebe T; Laaksonen R; Liuba P
Eur Heart J Open; 2024 Mar; 4(2):oeae026. PubMed ID: 38659666
[TBL] [Abstract][Full Text] [Related]
17. Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial.
Targher G; Lunardi G; Mantovani A; Meessen J; Bonapace S; Temporelli PL; Nicolis E; Novelli D; Conti A; Tavazzi L; Maggioni AP; Latini R
ESC Heart Fail; 2020 Dec; 7(6):3288-3297. PubMed ID: 32627354
[TBL] [Abstract][Full Text] [Related]
18. Association between Higher Circulating Leucine-Rich α-2 Glycoprotein 1 Concentrations and Specific Plasma Ceramides in Postmenopausal Women with Type 2 Diabetes.
Mantovani A; Csermely A; Sani E; Beatrice G; Petracca G; Lunardi G; Bonapace S; Lippi G; Targher G
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883498
[TBL] [Abstract][Full Text] [Related]
19. Circulating Ceramide: A New Cardiometabolic Biomarker in Patients With Comorbid Acute Coronary Syndrome and Type 2 Diabetes Mellitus.
Cao R; Fang Z; Li S; Xu M; Zhang J; Han D; Hu W; Yan L; Wang Y; Fan L; Cao F
Front Physiol; 2020; 11():1104. PubMed ID: 33041846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
